Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1987 Sep;42(9):652–655. doi: 10.1136/thx.42.9.652

Use of bronchoalveolar lavage in the evaluation of methotrexate lung disease.

G M Akoun 1, C M Mayaud 1, J L Touboul 1, M F Denis 1, B J Milleron 1, J Y Perrot 1
PMCID: PMC460901  PMID: 3686455

Abstract

The results of bronchoalveolar lavage in three patients with a presumptive diagnosis of methotrexate induced lung disease are presented. Lavage fluid was characterised by the presence of large numbers of lymphocytes, which in two patients were predominantly lymphocytes of the T8 phenotype. These findings further support the hypothesis that immune mediated mechanisms may play a part in the pathogenesis of this disorder in some patients, and indicate that bronchoalveolar lavage may be helpful in the evaluation of patients suspected of having methotrexate induced lung disease.

Full text

PDF
652

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akoun G. M., Mayaud C. M., Milleron B. J., Perrot P. Y. Drug-related pneumonitis and drug-induced hypersensitivity pneumonitis. Lancet. 1984 Jun 16;1(8390):1362–1363. doi: 10.1016/s0140-6736(84)91864-6. [DOI] [PubMed] [Google Scholar]
  2. Clarysse A. M., Cathey W. J., Cartwright G. E., Wintrobe M. M. Pulmonary disease complicating intermittent therapy with methotrexate. JAMA. 1969 Sep 22;209(12):1861–1868. [PubMed] [Google Scholar]
  3. Cooper J. A., Jr, White D. A., Matthay R. A. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs. Am Rev Respir Dis. 1986 Feb;133(2):321–340. doi: 10.1164/arrd.1986.133.2.321. [DOI] [PubMed] [Google Scholar]
  4. Ettensohn D. B., Roberts N. J., Jr, Condemi J. J. Bronchoalveolar lavage in gold lung. Chest. 1984 Apr;85(4):569–570. doi: 10.1378/chest.85.4.569. [DOI] [PubMed] [Google Scholar]
  5. Gutin P. H., Green M. R., Bleyer W. A., Bauer V. L., Wiernik P. H., Walker M. D. Methotrexate pneumonitis induced by intrathecal methotrexate therapy: a case report with pharmacokinetic data. Cancer. 1976 Oct;38(4):1529–1534. doi: 10.1002/1097-0142(197610)38:4<1529::aid-cncr2820380414>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  6. Kris M. G., Pablo D., Gralla R. J., Burke M. T., Prestifilippo J., Lewin D. Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy. Cancer Treat Rep. 1984 Jul-Aug;68(7-8):1029–1031. [PubMed] [Google Scholar]
  7. Luedke D., McLaughlin T. T., Daughaday C., Luedke S., Harrison B., Reed G., Martello O. Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression. Cancer. 1985 Feb 1;55(3):542–545. doi: 10.1002/1097-0142(19850201)55:3<542::aid-cncr2820550312>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  8. Reynolds H. Y., Newball H. H. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med. 1974 Oct;84(4):559–573. [PubMed] [Google Scholar]
  9. Sostman H. D., Matthay R. A., Putman C. E., Smith G. J. Methotrexate-induced pneumonitis. Medicine (Baltimore) 1976 Sep;55(5):371–388. doi: 10.1097/00005792-197609000-00002. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES